Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib vs chemotherapy in ZM fusion-positive recurrent secondary glioblastoma
ChiCTR2300077783Phase 3Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vebreltinib in glioblastoma (GBM) (4 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Overall survival. Started Oct 2018; status: completed.
02
Drugs
vebreltinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2300077783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077783.